UniQure starts $150 mln equity offering following FDA U-turn

Stifel Financial

22/06/2026 21:56

** UniQure NV QURE.O looks to raise equity just days after U.S. FDA reversed its earlier position on the Dutch drugmaker's Huntington's disease treatment
** QURE kicks off $150 mln offering of stock and pre-funded warrants
** Co's U.S.-listed shares surged ~78% to close at $48.16 on Weds after U.S. health regulator said it will accept existing trial data for an accelerated review of AMT-130
** Leerink Partners and Stifel joint bookrunners for the equity offering
** U.S.-listed QURE shares finished down 4.1% at $44.39 on Mon. In extended trading, they are up 1.9% to $45.22
** QURE has ~63.1 mln shares outstanding for $2.8 bln current market cap
     

(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))